Amneal Pharmaceuticals, Inc. (AMRX) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, and welcome to today's Amneal Pharmaceuticals Investor Call. I will now turn the call over to Amneal's Head of Investor Relations, Tony DeMeo. Good morning, and thank you for joining Amneal Pharmaceuticals' investor call. This morning, we issued a press release announcing Amneal agrees to acquire Kashyyb Biosciences and reporting preliminary q one results. The press release and presentation are available at amneal.com. Certain statements made on this call regarding matters that are not historical facts, including but not limited to management's outlook or predictions are forward looking statements that are based solely on information that is now available to us. Please see the section entitled Cautionary Statements on Forward Looking Statements for Factors that May Impact Future Performance. We also discuss non GAAP measures. Information on use of these measures and reconciliations to GAAP are in the press release and presentation. On the call today are Sharag and Shintu Patel, cofounders and co CEOs, Tatas Konenderis, CFO, and Jason Daley, chief legal officer. I will now hand the call over to Sharag. Thank you, Tony. Today is a defining moment for Amneal. This morning, we announced that Amneal agrees to acquire Kashuk Biosciences, creating a fully integrated global biosimilars leader and positioning Amneal to become the number one affordable medicines company in The United States. We have long said this was our goal, and today, we're showing exactly how to get there. Turning to slide three, I'll begin the call by discussing the strategic fit of the acquisition and the remarkable biosimilar opportunity ahead. Shintu will share more about Kashiv, our combined capabilities, and the robust biosimilar portfolio we will have. Tasuz will discuss the transacti...